Coherus Biosciences Inc (NASDAQ:CHRS) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $30.29.
CHRS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Coherus Biosciences in a report on Monday, November 25th. Credit Suisse Group reiterated a “buy” rating and issued a $36.00 price target on shares of Coherus Biosciences in a report on Friday, November 8th. ValuEngine cut shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 10th. TheStreet upgraded shares of Coherus Biosciences from a “d-” rating to a “c-” rating in a report on Thursday, November 7th. Finally, Mizuho initiated coverage on shares of Coherus Biosciences in a report on Wednesday, November 27th. They set a “buy” rating and a $43.00 target price on the stock.
NASDAQ:CHRS traded up $0.05 during trading hours on Thursday, hitting $19.86. The company had a trading volume of 21,541 shares, compared to its average volume of 914,471. The company has a market capitalization of $1.39 billion, a PE ratio of -6.18 and a beta of 2.89. The stock has a 50-day moving average price of $18.16 and a 200 day moving average price of $19.25. Coherus Biosciences has a 52 week low of $10.83 and a 52 week high of $23.91. The company has a debt-to-equity ratio of 3.37, a current ratio of 3.34 and a quick ratio of 3.25.
In other news, CFO Jean-Frederic Viret sold 1,388 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $19.02, for a total transaction of $26,399.76. Following the sale, the chief financial officer now owns 6,385 shares in the company, valued at approximately $121,442.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Vincent R. Anicetti sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $18.69, for a total transaction of $46,725.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 837,659 shares of company stock worth $15,091,914. Company insiders own 18.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Cutler Group LP bought a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $32,000. Tower Research Capital LLC TRC bought a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $52,000. Public Employees Retirement System of Ohio bought a new stake in shares of Coherus Biosciences during the 2nd quarter valued at $75,000. Hoey Investments Inc. bought a new stake in shares of Coherus Biosciences during the 4th quarter valued at $66,000. Finally, Bank of Montreal Can bought a new position in Coherus Biosciences in the 2nd quarter worth about $114,000. Hedge funds and other institutional investors own 98.62% of the company’s stock.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.